NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

ic,

I ran your post through the detector and it was identified as bs 😶




The statement by “iclight” is overwhelmingly comprised of unsubstantiated claims and aligns with the characteristics of disinformation. It egregiously misinterprets or distorts crucial aspects of the DCVax®-L Phase 3 trial and overlooks established norms in clinical research.

1. **Statistical Analysis Plan (SAP) Development**: The claim that an SAP is developed only after treatment completion is profoundly misleading. SAPs in clinical trials are conventionally established and finalized prior to data analysis, post-treatment but before unblinding the data. This protocol is pivotal to guarantee unbiased analysis aligned with pre-set plans. The insinuation otherwise is a gross misrepresentation of standard clinical procedures.

2. **Endpoint Changes**: The criticism regarding endpoint changes post-trial is taken out of context and demonstrates a lack of understanding of clinical trial dynamics. Adjustments to primary endpoints, while ideally set at the trial's inception, can be necessary, particularly in prolonged trials. Such adjustments are not made arbitrarily but under strict regulatory scrutiny and ethical oversight.

3. **Regulatory Authorities**: The continuous collaboration between NIH and FDA, and NIH’s extended support for Dr. Liau's research, lend credence to the trial's regulatory compliance and integrity.

4. **Peer Review and Publication**: The trial findings were published in the esteemed JAMA Oncology journal, indicative of a thorough peer-review process. This process is instrumental in validating the research's reliability and authenticity. The publication of these peer-reviewed results stands as a testament to the trial's credibility.

5. **Concerns in Other Publications**: While "Rev Neurol (Paris)" highlighted some methodological concerns regarding the DCVax®-L trial, these are primarily opinions focusing on trial design and reportage alterations, not on ethical violations or misconduct.

It is imperative to underscore the irresponsibility and potential harm of propagating rumors or participating in “short and distort” tactics, which involve spreading misleading information to manipulate market perceptions. Such actions not only mislead the public but can also unjustly harm the reputation of scientific endeavors and researchers.

In conclusion, the statement not only misrepresents the DCVax®-L Phase 3 trial but also demonstrates a disregard for the fundamental principles of clinical research and regulatory oversight. Its dissemination as factual information is a disservice to the public and the scientific community. This kind of rhetoric should be met with skepticism and requires a more informed understanding of clinical trial protocols and regulatory frameworks.

https://brownneurosurgery.com/breakthrough-brain-cancer-vaccine/